Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors
READ MORE...
Pneumagen Creates International Clinical Advisory Group of World Leading Respiratory and Infectious Disease Experts
READ MORE...
Pneumagen Announces First Patient Dosed in Phase 2 Proof of Concept Influenza Challenge Study Assessing Neumifil, an Intranasal Broad-Spectrum Antiviral
READ MORE...
Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections
READ MORE...
Pneumagen Announces Appointment of John Beadle as Non-Executive Director
READ MORE...
Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022
READ MORE...
Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)
READ MORE...
Pneumagen initiates Phase 1 trial of Neumifil, a novel, intranasal pan anti-viral therapeutic for the prophylaxis and treatment of viral Respiratory Tract Infections
READ MORE...
Pneumagen Appoints New Head of Research to Expand its Anti-Viral Pipeline leveraging its Proprietary GlycoTarge™ Platform